The anti‐BLyS monoclonal antibody, belimumab, has been approved for the treatment of SLE,10, 11 and clinical studies and post‐marketing real‐world data attest to the efficacy and safety of belimumab.12, 13, 14. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.